A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome

Trial Profile

A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Acamprosate (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Synchroneuron
  • Most Recent Events

    • 14 Apr 2016 Status changed from recruiting to completed.
    • 04 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 04 Sep 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top